{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:41:22Z","timestamp":1790185282982,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy is an important therapeutic modality for resectable nonsmall cell lung cancer (NSCLC). The roles of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio in predicting the efficacy and prognosis of patients with resectable NSCLC receiving neoadjuvant chemoimmunotherapy remain uncertain. This study aimed to explore the association of baseline and preoperative NLR, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio with the treatment response and survival of patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>Data of patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy between May 2019 and July 2022 at our institute, were retrospectively analyzed. Peripheral blood cell counts were obtained at baseline and before surgery. Data that may affect treatment efficacy were also collected and analyzed, including age, sex, BMI, cumulative smoking exposure, pathological type, clinical stage, PD-L1 tumor proportion score, immune checkpoint inhibitors, dosage of neoadjuvant therapy, duration from final therapy to surgery, and baseline and preoperative oncological markers. The present work has been reported in compliance with REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria and guidelines (Supplemental Digital Content 1, http:\/\/links.lww.com\/JS9\/A860).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 116 patients were included in the study. Univariate logistic regression analysis showed that a higher baseline NLR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001) and preoperative NLR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001) were associated with a lower incidence of pathological complete response (pCR) following neoadjuvant therapy. Multivariate analysis indicated that a lower incidence of pCR was achieved in the high baseline NLR group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.014). Higher baseline NLR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.021), preoperative NLR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004) and higher preoperative CEA levels (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.059) were associated with shorter disease-free survival (DFS). Multivariate Cox proportional hazard regression analyses showed that shorter DFS was achieved in the high preoperative NLR group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.033).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy, a higher baseline NLR was associated with a lower incidence of pCR, and a higher preoperative NLR was associated with a shorter DFS. However, a future prospective study with a large sample size and long-term follow-up is needed to verify the predictive value of NLR in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000000650","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T11:08:50Z","timestamp":1692011330000},"page":"3519-3526","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study"],"prefix":"10.1097","volume":"109","author":[{"given":"Wenliang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery"},{"name":"Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"},{"name":"Hunan Diagnosis and Treatment Center of Respiratory Disease"},{"name":"Research Unit of Respiratory Disease, Central South University, Changsha, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"},{"name":"Hunan Diagnosis and Treatment Center of Respiratory Disease"},{"name":"Research Unit of Respiratory Disease, Central South University, Changsha, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine"},{"name":"Hunan Diagnosis and Treatment Center of Respiratory Disease"},{"name":"Research Unit of Respiratory Disease, Central South University, Changsha, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery"},{"name":"Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery"},{"name":"Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Xiangya Hospital of Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery"},{"name":"Hunan Key Laboratory of Early Diagnosis and Precision Treatment of Lung Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R2-20250824","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.21037\/tlcr-21-634","article-title":"Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer","volume":"10","author":"Qiu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cllc.2019.11.017","article-title":"EPSILoN: a prognostic score using clinical and blood biomarkers in advanced non-small-cell lung cancer treated with immunotherapy","volume":"21","author":"Prelaj","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.21037\/tlcr-21-734","article-title":"Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients","volume":"10","author":"Yang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J Clin Oncol"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"587014","DOI":"10.3389\/fimmu.2020.587014","article-title":"Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses","volume":"11","author":"Kidman","year":"2020","journal-title":"Front Immunol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jtho.2017.11.132","article-title":"Stromal PD-L1-positive regulatory T cells and PD-1-Positive CD8-Positive T cells Define the response of different subsets of non-small cell lung cancer to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41598-019-57218-9","article-title":"Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Hwang","year":"2020","journal-title":"Sci Rep"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"e000405","DOI":"10.1136\/jitc-2019-000405","article-title":"Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort","volume":"8","author":"Mitchell","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.radonc.2018.02.025","article-title":"High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer","volume":"128","author":"Fang","year":"2018","journal-title":"Radiother Oncol"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.21037\/tlcr-20-760","article-title":"Emerging and multifaceted role of neutrophils in lung cancer","volume":"10","author":"Aloe","year":"2021","journal-title":"Transl Lung Cancer Res"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:09:21Z","timestamp":1756062561000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000000650","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"2023-04-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}